SI3630164T1 - Dulaglutid za zdravljenje kronične ledvične bolezni - Google Patents
Dulaglutid za zdravljenje kronične ledvične bolezniInfo
- Publication number
- SI3630164T1 SI3630164T1 SI201830979T SI201830979T SI3630164T1 SI 3630164 T1 SI3630164 T1 SI 3630164T1 SI 201830979 T SI201830979 T SI 201830979T SI 201830979 T SI201830979 T SI 201830979T SI 3630164 T1 SI3630164 T1 SI 3630164T1
- Authority
- SI
- Slovenia
- Prior art keywords
- dulaglutide
- treatment
- kidney disease
- chronic kidney
- chronic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/34—Genitourinary disorders
- G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513556P | 2017-06-01 | 2017-06-01 | |
| EP18730908.3A EP3630164B1 (en) | 2017-06-01 | 2018-05-24 | Dulaglutide for the treatment of chronic kidney disease |
| PCT/US2018/034278 WO2018222472A1 (en) | 2017-06-01 | 2018-05-24 | Dulaglutide for the treatment of chronic kidney disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3630164T1 true SI3630164T1 (sl) | 2023-10-30 |
Family
ID=62598054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201830979T SI3630164T1 (sl) | 2017-06-01 | 2018-05-24 | Dulaglutid za zdravljenje kronične ledvične bolezni |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20200171129A1 (sl) |
| EP (2) | EP4279925A3 (sl) |
| JP (2) | JP7191043B2 (sl) |
| CN (1) | CN110650747A (sl) |
| CA (1) | CA3065295C (sl) |
| DK (1) | DK3630164T3 (sl) |
| ES (1) | ES2963464T3 (sl) |
| FI (1) | FI3630164T3 (sl) |
| HR (1) | HRP20231093T1 (sl) |
| HU (1) | HUE063776T2 (sl) |
| LT (1) | LT3630164T (sl) |
| PL (1) | PL3630164T3 (sl) |
| PT (1) | PT3630164T (sl) |
| RS (1) | RS64666B1 (sl) |
| SI (1) | SI3630164T1 (sl) |
| WO (1) | WO2018222472A1 (sl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3713593A2 (en) | 2017-11-21 | 2020-09-30 | Eli Lilly and Company | Methods of using and compositions containing dulaglutide |
| CA3056663C (en) | 2019-04-05 | 2022-10-18 | Jeffrey S. RIESMEYER | Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus |
| CN117143242B (zh) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | 抗Galectin-3蛋白的单克隆抗体组合物及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1641823T1 (sl) | 2003-06-12 | 2011-12-30 | Lilly Co Eli | Fuzijski proteini analogni glp-1 |
| WO2009009562A2 (en) | 2007-07-10 | 2009-01-15 | Eli Lilly And Company | Glp-1-fc fusion protein formulation |
| JP6034781B2 (ja) * | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
| CN105324126A (zh) * | 2013-06-21 | 2016-02-10 | 诺和诺德股份有限公司 | Glp-1受体激动剂在用胰岛素治疗的和/或患有1型糖尿病的患者中的新用途 |
-
2018
- 2018-05-24 PL PL18730908.3T patent/PL3630164T3/pl unknown
- 2018-05-24 FI FIEP18730908.3T patent/FI3630164T3/fi active
- 2018-05-24 EP EP23188793.6A patent/EP4279925A3/en active Pending
- 2018-05-24 HU HUE18730908A patent/HUE063776T2/hu unknown
- 2018-05-24 DK DK18730908.3T patent/DK3630164T3/da active
- 2018-05-24 SI SI201830979T patent/SI3630164T1/sl unknown
- 2018-05-24 WO PCT/US2018/034278 patent/WO2018222472A1/en active Application Filing
- 2018-05-24 HR HRP20231093TT patent/HRP20231093T1/hr unknown
- 2018-05-24 ES ES18730908T patent/ES2963464T3/es active Active
- 2018-05-24 US US16/615,609 patent/US20200171129A1/en not_active Abandoned
- 2018-05-24 JP JP2019565364A patent/JP7191043B2/ja active Active
- 2018-05-24 PT PT187309083T patent/PT3630164T/pt unknown
- 2018-05-24 LT LTEPPCT/US2018/034278T patent/LT3630164T/lt unknown
- 2018-05-24 RS RS20230908A patent/RS64666B1/sr unknown
- 2018-05-24 CN CN201880033295.9A patent/CN110650747A/zh active Pending
- 2018-05-24 EP EP18730908.3A patent/EP3630164B1/en active Active
- 2018-05-24 CA CA3065295A patent/CA3065295C/en active Active
-
2022
- 2022-09-27 JP JP2022153483A patent/JP2023002547A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PL3630164T3 (pl) | 2024-01-29 |
| EP3630164B1 (en) | 2023-08-23 |
| LT3630164T (lt) | 2023-10-25 |
| US20200171129A1 (en) | 2020-06-04 |
| ES2963464T3 (es) | 2024-03-27 |
| HUE063776T2 (hu) | 2024-01-28 |
| RS64666B1 (sr) | 2023-11-30 |
| WO2018222472A1 (en) | 2018-12-06 |
| EP3630164A1 (en) | 2020-04-08 |
| JP7191043B2 (ja) | 2022-12-16 |
| DK3630164T3 (da) | 2023-10-02 |
| CN110650747A (zh) | 2020-01-03 |
| JP2023002547A (ja) | 2023-01-10 |
| CA3065295A1 (en) | 2018-12-06 |
| EP4279925A3 (en) | 2024-01-24 |
| JP2020521765A (ja) | 2020-07-27 |
| PT3630164T (pt) | 2023-09-14 |
| FI3630164T3 (fi) | 2023-11-06 |
| HRP20231093T1 (hr) | 2023-12-22 |
| EP4279925A2 (en) | 2023-11-22 |
| CA3065295C (en) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289650A (en) | Azolopyrimidine for the treatment of cancer-related disorders | |
| HK1251257A1 (zh) | 用於醫治疾病的外泌體的用途 | |
| IL253945A0 (en) | kdm1a inhibitors to treat the disease | |
| EP3402516A4 (en) | USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER | |
| HK1247129A1 (zh) | 治療癌症的聯合療法 | |
| HK1251475A1 (zh) | 用於癌症治療的聯合療法 | |
| ZA201806819B (en) | Pharmaceutical combinations for the treatment of cancer | |
| IL282007A (en) | Medicine to treat chronic cough | |
| IL269357A (en) | Combined therapies for the treatment of breast cancer | |
| HUE063776T2 (hu) | Dulaglutid krónikus vesebetegség kezelésére | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| EP3111934A4 (en) | Agent for improving or preventing progression of chronic kidney disease | |
| RS64798B1 (sr) | Upotreba delgocitiniba za lečenje hroničnog ekcema šaka | |
| GB201904184D0 (en) | Fluid treatment | |
| IL272422A (en) | Methods for treating diseases of the meninges | |
| GB201809077D0 (en) | Fluid treatment | |
| GB201811629D0 (en) | Venous disease | |
| GB201713936D0 (en) | Pharmaceutical combinations for the treatment of cancer | |
| EP3854402C0 (en) | TREATMENT OR PREVENTION OF GRAFT-VERSE-HOST DISEASE | |
| AU2015900978A0 (en) | Compositions for the treatment of kidney disease |